Vaxcyte (PCVX) reported a full-year 2024 net loss late Tuesday of $3.80 per diluted share, narrower than a per-share loss of $4.14 a year earlier.
Analysts polled by FactSet expected a per-share loss of $3.91.
The company said it had cash, cash equivalents and investments of $3.13 billion as of Dec. 31, up from $1.24 billion a year earlier. Vaxcyte said the increase was mainly due to $2.2 billion in net proceeds from two follow-on financings last year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。